Form 8-K - Current report:
SEC Accession No. 0001711279-23-000010
Filing Date
2023-02-27
Accepted
2023-02-27 07:25:30
Documents
14
Period of Report
2023-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K krys-20230227.htm   iXBRL 8-K 39651
2 EX-99.1 krys12312022-ex991pressrel.htm EX-99.1 81492
6 image_0a.jpg GRAPHIC 187260
  Complete submission text file 0001711279-23-000010.txt   504181

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT krys-20230227.xsd EX-101.SCH 1914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT krys-20230227_lab.xml EX-101.LAB 22164
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT krys-20230227_pre.xml EX-101.PRE 11598
8 EXTRACTED XBRL INSTANCE DOCUMENT krys-20230227_htm.xml XML 9791
Mailing Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203
Business Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203 (412) 586-5830
Krystal Biotech, Inc. (Filer) CIK: 0001711279 (see all company filings)

EIN.: 821080209 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38210 | Film No.: 23670041
SIC: 2836 Biological Products, (No Diagnostic Substances)